Core Viewpoint - The 27th China Association for Science and Technology Annual Conference held on July 6 in Beijing announced 10 frontier scientific issues, 10 engineering technical challenges, and 10 industrial technology problems for 2025, aiming to promote original and disruptive scientific achievements [2]. Frontier Scientific Issues - The ten frontier scientific issues include: 1. Topological and geometric classification of manifolds 2. Properties of the Higgs boson and the origin of mass 3. Feasibility study of using post-transition metals as substitutes for transition metals in precise synthesis and catalytic reactions 4. Anomalies in typhoon paths and intensity mutations 5. Mechanisms of spatial pattern formation in macro-ecosystems and interactions between systems 6. New theories and protective systems for AI security from a cryptographic perspective 7. Multi-dimensional, reconfigurable supramolecular machine assembly 8. Dark energy and the Hubble constant crisis 9. Breeding potential of wild relatives of crops in enhancing stress resistance traits 10. Interaction regulation mechanisms between human microecology and hosts [4]. Engineering Technical Challenges - The ten engineering technical challenges include: 1. Integrated algorithms and theories for complex model design-simulation-manufacturing 2. Deep-sea large-scale mining equipment and environmental disturbance suppression 3. Collaborative utilization and governance technologies for regional surface water, groundwater, reclaimed water, external water, and seawater 4. Intelligent network technology system for communication and smart integration 5. Biomanufacturing of complex organs 6. Integrated development technology for coal and associated energy resources 7. Next-generation low-energy, low-cost carbon capture and storage technology 8. Energy integration and intelligent management for advanced airborne systems 9. Biomanufacturing technology for bulk food raw materials and high-value ingredients 10. Establishing a new drug development system based on clinical and multi-omics big data [5]. Industrial Technology Problems - The ten industrial technology problems include: 1. Breaking through the import bottleneck of high-end equipment for large and ultra-large seawater desalination projects 2. Enhancing the oxidation resistance of ultra-supercritical steam turbine blades 3. Research on key scientific and technological issues for autonomous mining in deep space resource development 4. Building an autonomous capability evaluation system for intelligent unmanned systems oriented towards industry 5. Industrial implementation of high-speed optical interconnect (optical I/O) technology between chips 6. Development of regenerative biomaterials in aging states 7. Pathways to achieve a comprehensive balance of "safety-low carbon-economy" in energy and electricity 8. Intelligent processing and industrial application of satellite remote sensing data 9. Intelligent response biological vaccines for pests and diseases driven by synthetic biology and AI 10. Brain function assessment and intelligent closed-loop intervention [6]. Instrument Demand - The R&D activities related to the 2025 issues will drive demand for various research instruments, including: - Precision measurement devices such as high-precision mass spectrometers and spectrometers for studying the properties of the Higgs boson [8]. - Astronomical observation equipment like large radio telescopes and optical telescopes for data support on dark energy and the Hubble constant crisis [8]. - Biochemical analysis instruments such as high-performance liquid chromatography (HPLC) and gas chromatography-mass spectrometry (GC-MS) for research on post-transition metal substitutes and human microecology [8]. - Advanced meteorological monitoring equipment for studying typhoon path anomalies [9]. - Simulation software and hardware for integrated algorithms in complex model design [10]. - Deep-sea exploration equipment for large-scale mining and environmental disturbance suppression [11]. - Communication testing devices for developing intelligent network technology systems [12]. - Life science research tools for biomanufacturing complex organs [13]. - Equipment related to seawater desalination technology [14]. - Energy efficiency assessment tools for achieving a balanced energy strategy [15]. - Satellite remote sensing data analysis platforms for intelligent processing and application [16].

Group 1 - The 42nd National Pharmaceutical Industry Information Annual Conference and the 2025 Beijing-Changping Life Science Forum were held in Beijing, focusing on the future development of the pharmaceutical industry through insights, ecosystem building, and resource integration [1][3] - The list of "Top 100 Enterprises in China's Pharmaceutical Industry by Main Business Revenue for 2024" was released, with Sichuan Good Doctor Panzhihua Pharmaceutical Co., Ltd. making the list for the 14th consecutive year, showcasing its sustained comprehensive strength [1][3] - Good Doctor Pharmaceutical Group Co., Ltd. received the "2025 China Pharmaceutical Industry Growth Potential Enterprise Map" award, reflecting industry recognition of its future development potential [1][3] Group 2 - The annual conference has been a significant event since its inception in 1959, witnessing the growth and technological innovation of China's pharmaceutical industry [3] - The conference aims to promote the integration of cutting-edge technological innovation concepts with resources from top pharmaceutical companies, driving innovation and transformation in the industry [3] - The global biopharmaceutical industry is undergoing profound changes, with advancements in AI, synthetic biology, gene editing, and cell therapy accelerating China's pharmaceutical industry's shift towards innovation and high-end development [3] Group 3 - In 2024, Good Doctor Group will invest over 800 million yuan to establish a digital intelligent factory for the production of biological raw materials and large-scale traditional Chinese medicine, enhancing production efficiency and product quality [4] - The construction of the second phase of the digital intelligent factory not only improves the production capacity and level of traditional Chinese medicine but also serves as a model for digital projects, promoting high-quality development in the pharmaceutical production sector in Xichang and Liangshan [4]

Core Viewpoint - The article highlights the upcoming Synbio China 2025 event, focusing on the integration of scientists, entrepreneurs, and investors in the field of synthetic biology, emphasizing its strategic importance for the development of China's bio-economy [33]. Event Details - The Synbio China 2025 event will take place on August 1-2, 2025, at the Suzhou International Expo Center, alongside the 7th CMC-China Expo [1]. - Confirmed attendees include experts from various universities such as Beijing University of Chemical Technology, Shanghai Jiao Tong University, and East China University of Science and Technology, as well as representatives from companies like Micro Factory and Henan Biological Industry Group [2]. Agenda Highlights - The agenda includes lectures from academicians and experts, covering topics such as the opportunities and challenges in the industrialization of synthetic biology, and innovative pathways for non-grain biomass potential [6][7]. - Specific sessions will focus on enabling technologies, including enzyme engineering and CRISPR/Cas9 applications, as well as the development of bio-based materials and their industrial applications [8][10]. Industry Challenges - The article discusses the rapid dissemination of synthetic biology concepts in China, while also addressing challenges such as achieving scalable production, realizing the value of synthetic biological products, and fostering innovation in core competitiveness [33]. Networking Opportunities - The event aims to facilitate face-to-face interactions among founders, industry experts, investors, and government representatives, providing a platform for project promotion and industry guidance [35]. Participation and Registration - Attendees are encouraged to register for free through a QR code provided in the article, ensuring access to the event and its networking opportunities [4][12]. Additional Information - The 7th CMC-China Expo is expected to attract around 20,000 participants, featuring 450 exhibiting companies and 600 invited guests, with multiple forums dedicated to cutting-edge topics in the industry [79].

Project Overview - The project involves the establishment of a thousand-ton bio-based product production line, focusing on 1,3-PDO, calcium lactate, vanillin, and sialic acid processing [3] - The total investment for the project is 50 million yuan, with 5 million yuan allocated for environmental protection [3] - The production capacity upon completion will be 720 tons of 1,3-PDO, 940 tons of calcium lactate, 30 tons of vanillin, and 10 tons of sialic acid annually [3] Company Background - Si Peng Bio-materials (Nantong) Co., Ltd. is a wholly-owned subsidiary of Shanghai Si Peng Technology Co., Ltd., established in May 2022 [4] - The company focuses on negative carbon synthetic biology and is led by a team of scientists from Shanghai Jiao Tong University [4] - It has developed a unique one-step method for synthesizing polylactic acid (PLA) from carbon dioxide, achieving a 70% reduction in carbon emissions [4] - The company has partnered with Angel Yeast to establish a thousand-ton production line, with products including bio-based polyols and biodegradable plastics [4] Industry Insights - The bio-based materials sector is witnessing significant developments, with various companies making strides in bio-manufacturing technologies [8] - The market for bio-based materials is projected to grow substantially, indicating a competitive landscape for companies involved in this field [8]

Core Insights - Sinopec (Dalian) Petrochemical Research Institute is recruiting for 11 positions in key areas such as solid-state batteries, petrochemical artificial intelligence, bio-based monomers and materials, and synthetic biology, offering attractive annual salaries ranging from 500,000 to 2,000,000 CNY and 10 million CNY in research startup funding [1]. Group 1: Recruitment Details - The recruitment focuses on experts in synthetic biology, petrochemical engineering plastics, and bio-based monomers and materials [2][3][4]. - Each position requires a PhD, candidates aged between 30-50 years, and a minimum of 10 years of relevant work experience, with flexibility for outstanding candidates [5][5][5]. Group 2: Job Responsibilities and Requirements - Responsibilities include formulating strategic plans for carbon gas bioconversion, developing strain modification and biocatalysis systems, and leading product development and market promotion [5]. - The positions also involve planning the development strategy for special engineering plastics and bio-based materials, with a focus on technology development and market promotion [5][5][5]. Group 3: Compensation and Benefits - The salary range is between 500,000 to 2,000,000 CNY per year, with additional relocation allowances of 1.2 to 5 million CNY for high-level talent [7]. - The company provides 10 million CNY in research startup funding, a well-equipped research team of 3-8 members, and various support for relocation, education, and employment for family members [7]. Group 4: Upcoming Events - The 4th Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22, 2025, in Ningbo, Zhejiang, focusing on AI and bio-manufacturing, green chemicals, new materials, future food, agriculture, and beauty raw materials [8]. - The conference aims to explore the development trends in the bio-manufacturing industry and promote the transfer and transformation of scientific achievements [8].

Core Viewpoint - The era of producing high-value products from CO₂ in the air has arrived, marking significant industrial advancements in the biomanufacturing conversion of carbon-rich gases [1][2]. Group 1: Industrial Challenges and Innovations - The Ministry of Agriculture and Rural Affairs of China has officially approved the use of Debaryomyces hansenii protein as a new feed raw material, representing the first product certificate with independent intellectual property rights derived from CO₂ as the main carbon source [2][4]. - This approval signifies a critical step in the industrial application of this technology, transitioning from laboratory research to practical use [2][4]. - The gas fermentation technology developed by GTLB utilizes inorganic carbon sources (CO₂, CO) to convert them into organic products, overcoming significant industrial challenges [4][6]. Group 2: Production Efficiency and Nutritional Value - The feed protein produced using this gas fermentation technology can achieve production efficiency thousands of times higher than traditional agricultural methods [7]. - A yeast protein factory occupying 150 acres can produce 100,000 tons of high-quality yeast protein annually, equivalent to the output of approximately 600,000 acres of soybean protein [8]. - Yeast protein is recognized for its high and evenly distributed essential amino acid content, rich in trace elements and polysaccharides, making it a safe and high-quality protein source [9]. Group 3: Addressing Resource Shortages - China faces a severe shortage of feed protein resources, with an estimated total consumption of 70 million tons in 2024 and an import dependency exceeding 80%, posing a significant threat to national food security [11]. - The innovative technology aligns with national strategies to develop synthetic biology technologies and explore "artificial protein" as a new food source, aiming to reduce reliance on traditional protein sources like soybean and fishmeal [12]. - The approval of Debaryomyces hansenii protein as a single feed raw material will help create a more sustainable and resource-efficient protein feed supply chain, significantly reducing dependence on land-intensive crops and marine resources [12].

Core Viewpoint - Zhejiang Province is accelerating the innovation and development of the synthetic biology industry, aiming for a total industry scale of 150 billion by 2027, with core enterprises achieving a production value of 20 billion [1][2]. Group 1: Industry Development Plan - The "Implementation Plan for Accelerating the Innovation and Development of the Synthetic Biology Industry in Zhejiang Province" outlines six major development directions, eleven regional industrial layouts, key tasks for nine universities and research institutes, and ten core technology breakthroughs [1][2]. - The plan aims to establish an internationally influential synthetic biology industry innovation development hub in Zhejiang [1]. Group 2: Alliance Formation - The Zhejiang Synthetic Biology Industry Technology Alliance, guided by the Zhejiang Provincial Department of Economy and Information Technology, is a non-profit organization initiated by Zhejiang University Hangzhou International Innovation Center, aiming to promote technological innovation and industry cultivation [2]. - The alliance will leverage the advantages of Zhejiang University in talent cultivation, technological innovation, and high-level platforms to support the synthetic biology industry [2]. Group 3: Research and Development Facilities - The Zhejiang University Hangzhou International Innovation Center has established the Bio and Molecular Manufacturing Research Institute and the iBioFoundry, the largest and most integrated automated high-throughput scientific device in the field globally [4]. - This facility enables full-process automation from sample intelligent access to product detection and is now open as a shared research platform for teams and enterprises [4]. Group 4: Upcoming Conference - The 2025 Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, Zhejiang, focusing on AI and biological manufacturing, as well as four application areas: green chemicals and new materials, future food, future agriculture, and beauty raw materials [6][8]. - The conference aims to explore the development trends of the bio-manufacturing industry and promote the transfer and transformation of scientific and technological achievements [6].

Group 1 - Industry Investment Rating: Overweight [1] - Core Viewpoint: The chemical sector's overall performance ranked 16th with a fluctuation of 0.80%, underperforming the Shanghai Composite Index by 0.60 percentage points [4][22] - Key Recommendations: Focus on synthetic biology, pesticides, chromatography media, sugar substitutes, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] Group 2 - Synthetic Biology: A pivotal moment is approaching, with low-energy products expected to gain a longer growth window due to the energy structure adjustment [4] - Refrigerants: The third-generation refrigerants are entering a high prosperity cycle, with supply constraints and stable demand growth anticipated [5] - Electronic Specialty Gases: The domestic market faces a contradiction between rapid upgrades in wafer manufacturing and insufficient high-end electronic specialty gas capacity, presenting significant domestic substitution opportunities [6][8] - Light Hydrocarbon Chemicals: A global trend towards lighter raw materials in the olefin industry is noted, with a shift from heavy naphtha to lighter ethane and propane [8] - COC Polymers: The domestic industrialization process is accelerating, driven by breakthroughs in local enterprises and a shift in downstream industries to domestic production [9] - Potash Fertilizer: Prices are expected to bottom out and rebound due to supply reductions and increased demand from farmers [10] - MDI Market: The oligopoly structure is expected to improve, with demand steadily increasing and a favorable supply outlook anticipated [12]

Core Viewpoint - Micro Yuan Synthetic's allulose has received administrative approval from the National Health Commission, making it the first company in China to produce allulose through a biological fermentation process, which is a significant milestone in the synthetic biology industry [1][3]. Company Summary - Micro Yuan Synthetic has developed a unique "one-step fermentation method" for producing allulose, increasing conversion efficiency to 80% and reducing production costs by 50% [3]. - The AS10 strain used in production is described as an "intelligent cell factory" that can be infinitely replicated, promoting the industrial adaptation of engineered strains [3]. - The company aims to make allulose a widely used health sugar, addressing the domestic sugar supply gap while being beneficial for blood sugar control and weight management [1][2]. Industry Summary - The global focus on obesity and diabetes has led the pharmaceutical industry to seek safe sugar alternatives, with allulose being viewed as a promising candidate for large-scale application [2]. - The synthetic biology manufacturing sector is expanding into various fields, including biomedicine, food nutrition, and new materials, with significant policy support from local governments [5][6]. - The innovative production methods in synthetic biology not only enhance efficiency but also contribute to environmental sustainability by reducing land use and production costs [4][6].

Core Viewpoint - Guangdong Zhumei Biotechnology has achieved a significant breakthrough in the industrialization of natural high-intensity sweet protein by completing the first domestic pilot test of recombinant Brazzein using Pichia pastoris as the chassis cell, aiming for ton-level production capacity by 2026, which will greatly increase the yield of Brazzein [1][2]. Group 1: Characteristics of Brazzein - Brazzein is derived from the fruit of a wild plant in West Africa and is known to be 500-2000 times sweeter than sucrose, making it one of the sweetest natural substances known to humans [4]. - It maintains stability across a pH range of 2.5-8 and retains its sweetness even after being heated at 80°C for 4 hours or 98°C for 2 hours [5]. - As a protein, Brazzein is easily digested into amino acids, has no impact on blood sugar, and poses no health risks [6]. - It offers a clean taste similar to sucrose without metallic or bitter aftertastes, making it suitable for widespread application in the food industry [6]. - Research indicates that Brazzein may possess anti-inflammatory and antioxidant properties, with similarities to antimicrobial peptides, providing some antibacterial and antifungal activity [6]. Group 2: Market Potential and Challenges - The global market for Brazzein was valued at $500 million in 2023 and is projected to reach $790 million by 2029 [7]. - Traditional extraction methods yield very low extraction rates (~0.2%), making precision fermentation and genetic engineering the most promising methods for developing Brazzein [7]. - Current microbial expression systems face challenges such as low protein expression levels, incorrect protein folding leading to reduced activity, and complex, costly purification processes, which limit the widespread application of sweet proteins [9]. Group 3: Industry Developments - In May 2023, Sweegen successfully produced Brazzein using precision fermentation and became the first to receive FEMA GRAS certification [11]. - In 2024, Oobli's Brazzein production received FDA GRAS certification for general food applications, and they announced a partnership with Ingredion to advance sweet protein applications [11]. - Ginkgo Bioworks and GreenLab are collaborating to enhance Brazzein expression in corn and scale up production through precision fermentation [11]. - Waterdrop Farm also achieved FDA SELF-GRAS status in March 2025, becoming one of the few companies to commercialize Brazzein [11]. Group 4: Company Overview - Guangdong Zhumei Biotechnology is a high-tech enterprise specializing in the research, production, and sales of synthetic biology products, with a 1000 square meter intelligent research center [12]. - The company utilizes synthetic biology technology to efficiently produce various products, including recombinant human collagen, astaxanthin, beta-carotene, antimicrobial peptides, and lysozyme [12].